Department of Health and Human Services February 22, 2011 – Federal Register Recent Federal Regulation Documents

Proposed Data Collections Submitted for Public Comment and Recommendations
Document Number: 2011-3936
Type: Notice
Date: 2011-02-22
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Notice of Allotment Percentages to States for Child Welfare Services State Grants
Document Number: 2011-3919
Type: Notice
Date: 2011-02-22
Agency: Department of Health and Human Services, Administration for Children and Families
As required by section 423(c) of the Social Security Act (42 U.S.C. 623(c)), the Department is publishing the allotment percentage for each State under the Title IV-B Subpart 1, Child Welfare Services State Grants Program. Under section 423(a), the allotment percentages are one of the factors used in the computation of the Federal grants awarded under the Program.
HIT Standards Committee Advisory Meeting; Notice of Meeting
Document Number: 2011-3842
Type: Notice
Date: 2011-02-22
Agency: Department of Health and Human Services
NIOSH Dose Reconstruction Program Ten Year Review-Phase I Report on Quality of Science; Request for Public Review and Comment
Document Number: 2011-3823
Type: Notice
Date: 2011-02-22
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
NIOSH requests public review and comment on the draft publication, ``NIOSH Dose Reconstruction Program Ten Year ReviewPhase I Report on Quality of Science.'' This publication is part of a review by NIOSH of its program in support of the role of the Secretary of Health and Human Services under the Energy Employees Occupational Illness Compensation Program Act of 2000 (The Act). As stated in NIOSH Docket 194, Phase I of the review is a data-driven assessment of the dose reconstruction program. The information provided in Phase I will be used by NIOSH in considering recommendations for improving the program during Phase II of the review. This publication is the Phase I report on one of the five topics under consideration during the program review: The quality of science practiced by NIOSH in the program. The document can be found at https:// www.cdc.gov/niosh/docket/archive/docket194.html.
NIOSH Dose Reconstruction Program Ten-Year Review-Phase I Report on Customer Service; Request for Public Review and Comment
Document Number: 2011-3822
Type: Notice
Date: 2011-02-22
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
NIOSH requests public review and comment on the draft publication, ``NIOSH Dose Reconstruction Program Ten-Year ReviewPhase I Report on Customer Service.'' This publication is part of a review by NIOSH of its program in support of the role of the Secretary of Health and Human Services under the Energy Employees Occupational Illness Compensation Program Act of 2000 (The Act). As stated in NIOSH Docket 194, Phase I of the review is a data-driven assessment of the dose reconstruction program. The information provided in Phase I will be used by NIOSH in considering recommendations for improving the program during Phase II of the review. This publication is the Phase I report on one of the five topics under consideration during the program review: The customer service provided by NIOSH in the program. The document can be found at https:// www.cdc.gov/niosh/docket/archive/docket194.html.
Proposed Information Collection Activity; Comment Request
Document Number: 2011-3803
Type: Notice
Date: 2011-02-22
Agency: Department of Health and Human Services, Administration for Children and Families
Determination That Theophylline Oral Solution, 80 Milligrams/15 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Document Number: 2011-3784
Type: Notice
Date: 2011-02-22
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) has determined that theophylline oral solution, 80 milligrams (mg)/15 milliliters (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for theophylline oral solution, 80 mg/15 mL, if all other legal and regulatory requirements are met.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.